August 2008 - Veterinary Cancer Group is happy to welcome our newest medical oncology resident, Dr. Julie Bulman-Fleming. Dr. Bulman-Fleming joins us from Canada and will be working closely with Dr. Rosenberg in our Orange County facility.
Dr. Mona Rosenberg has been chosen as the honored diplomate at the 2nd annual ACVIM Foundation Paws for Cures Event!
The ACVIM Foundation Honors Dr. Mona Rosenberg of Veterinary Cancer Group in Culver City and Tustin, CA.
As the owner, CEO and Chief of Staff at the Veterinary Cancer Group, Dr. Rosenberg has been committed to helping pets fight cancer, while restoring hope in the hearts of their owners. Her two practices are the largest, most comprehensive and sophisticated oncology practices in the world, serving four counties in Southern California.
After receiving her DVM degree from the University of California, Davis, and completing her internship and residency at Animal Medical Center in New York, she went on to become an ACVIM Diplomate in 1992. She is an active member of the Veterinary Cancer Society and the SCVMA and was appointed Clinical Associate Professor of Veterinary Medicine at Western University of Health Sciences/College of Veterinary Medicine. She also leads the medical oncology residency program at Veterinary Cancer Group.
Dr. Rosenberg’s enhancements to the field of veterinary oncology have proved that even the toughest battles can be won with the help of specialty medicine and steadfast dedication. She has granted precious time and health to our beloved companions, and precious advancements in veterinary oncology to the world.
July 2008 - Dr. Sara Fiocchi completed her residency program and has joined the Orange County office as a Staff Doctor.
June 2008 - The results are in! Dr. Mary Davis has passed her certifying exam with the ACVIM. Following acceptance of her publication, she will be awarded diplomate status. Dr. Autumn Dutelle passed her qualifying exam, allowing her to sit for the certifying exam next year.
May 2008 - The Veterinary Cancer Group was recently featured in The Orange County Register on May 19th. Click here to read the article.OC Register
Spring 2008 - Congratulations to Dr. Sue Downing for being appointed Medical Director of the Culver City location. Great Job!
February 2008 - Veterinary Cancer Group is named as one of "California's Best Places to Work" for 2007. Veterinary Cancer Group has been ranked third in the growing company-size category of California's Best Places to Work program. This first-ever bet workplace program exclusively for California employers was sponsored by Employers Group, the preeminent human resources expert and advocate servicing California employers.
Clinical Trails - The Veterinary Cancer Group is pleased to be involved in an on-going basis with the latest clinical trials open for enrollment. As the largest private oncology practice in the nation, we are the ONLY southern California practice able to offer these fully funded and partially funded studies.
Ongoing.
- Solid Tumors (including Lymphoma): Dose-Escalating Study of Elsamitrucin (SPI 28090) – fully funded
- Histiocytic Sarcoma: Combined Use of Doxorubicin and CCNU
- Osteosarcoma: Combined Use of Carboplatin and Gemcitabine as Primary and Secondary-Line Treatment
- Canine Nasal Tumors: Use of Palliative-Course Radiation to Alleviate Symptoms
- Hemangiosarcoma: Combined Use of Doxorubicin and Low-Dose Daily Oral Chemotherapy
- Bladder Cancer: Relief of Urethral Obstruction by Temporary Catheterization and Palliative-Course Radiation with Sensitizer
- Multiple Myeloma: Use of a Novel Antiangiogenic Agent—fully funded Histiocytic Sarcomas: Combined Use of Doxorubicin and CCNU
Recently.
- Multiple Myeloma: Use of a Novel Antiangiogenic Agent—fully funded Histiocytic Sarcomas: Combined Use of Doxorubicin and CCNU
- Lymphoma: Use of PARP (Poly (ADP-Ribose) Polymerase) Inhibition combined with Multi-Agent Chemotherapy for Treatment in Dogs with Newly Diagnosed LSA—fully funded
- Lymphoma: Use of Antiangiogenic Peptide plus Chemotherapy for Treatment in Dogs with Newly Diagnosed LSA—fully funded
- Osteosarcoma: Use of ETa (Endothelin) Antagonist for the Treatment of Dogs with Pulmonary Metastasis from OSA—fully funded.